Evidence map›Paper›PMID 37303748›Full record

ArticleCase reports in medicine2023

The First Registered Type 0 Spinal Muscular Atrophy Patient in Latvia: Call for Change in Prenatal Diagnostic Procedures.

Tīna Luīze Čupāne, Mikus Dīriks, Gita Tauriņa, Liene Korņejeva, Linda Gailīte, Ieva Mālniece, Madara Auzenbaha

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Antenatal Ultrasound Findings in Spinal Muscular Atrophy Type 0.Molecular genetics & genomic medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Tīna Luīze ČupāneUniversity of Latvia, Faculty of Medicine, Riga, Latvia.ORCID https://orcid.org/0000-0001-5656-4073
Mikus DīriksEuropean Reference Network EURO-NMD, Paris, France.ORCID https://orcid.org/0009-0007-7871-0693
Gita TauriņaChildren's Clinical University Hospital (CCUH), Medical Genetics and Prenatal Diagnostic Clinic, Riga, Latvia.ORCID https://orcid.org/0000-0002-7101-6929
Liene KorņejevaThe Riga Maternity Hospital, Riga, Latvia.ORCID https://orcid.org/0009-0004-1136-3736
Linda GailīteRiga Stradins University, Scientific Laboratory of Molecular Genetics, Riga, Latvia.ORCID https://orcid.org/0000-0002-7219-1294
Ieva MālnieceChildren's Clinical University Hospital (CCUH), Medical Genetics and Prenatal Diagnostic Clinic, Riga, Latvia.
Madara AuzenbahaChildren's Clinical University Hospital (CCUH), Medical Genetics and Prenatal Diagnostic Clinic, Riga, Latvia.ORCID https://orcid.org/0000-0002-9925-2376
Children's Clinical University Hospital · LVEuropean Organisation for Rare Diseases · FRRiga East University Hospital · LVRiga Stradiņš University · LV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report presents the first registered patient in Latvia with type 0 spinal muscular atrophy (SMA). During the first-trimester ultrasonography of the unborn patient, an increased thickness of the nuchal fold was detected. The mother reported decreased foetal movements during the pregnancy. After the boy was born, his general condition was extremely severe. The clinical signs indicated a suspected neuromuscular disorder. A precise diagnosis, type 0 SMA, was determined 7 days after birth through a newborn pilot-screening for SMA, which was conducted for all newborns whose parents consented to participate. The condition of the infant deteriorated. He had severe respiratory distress followed by multiple events leading to his death. Currently, there are only a few published case reports detailing an increased nuchal translucency (NT) measurement in association with a diagnosis of SMA in the foetus. However, an increased NT measurement is a clinically relevant sign as it can be related to genetic syndromes, foetal malformations, disruptions, and dysplasias. Since there is no cure for infants with type 0 SMA at present, it is crucial to be able to detect this disease prenatally in order to provide the best possible care for the patient and parents. This includes the provision of palliative care for the patient, among other measures. This case report highlights the prenatal signs and symptoms in relation to type 0 SMA.

Identifiers

PMID37303748
PMCPMC10250090
OpenAlexW4378975726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.